Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia - Zhang, L; Zhang, ZG; Zhang, RL (Stroke, 2001)
et al.